Publication Topic

Thompson CM, Bichteler A, Rager JE, Suh M, Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008.

Thompson CM, Suh M, Mittal L, Wikoff D, Welsh B, Proctor DM. 2016. Development of linear and threshold no significant risk levels for inhalation exposure to titanium dioxide using systematic review and mode of action considerations. Regul Toxicol Pharmacol 80(Oct):60-70; doi: 10.1016/j.yrtph.2016.05.031. PMID: 27233922.

Becker RA, Patlewicz G, Simon T, Rowlands JC, Budinsky RA. 2015. The adverse outcome pathway for rodent liver tumor promotion by sustained activation of the aryl hydrocarbon receptor. Regul Toxicol Pharmacol 73(1):172-190; doi: 10.1016/j.yrtph.2015.06.015. PMID: 26145830.

Young RR, Thompson CM, Dinesdurage HR, Elbekai RH, Suh M, Rohr AC, Proctor DM. 2015. A robust method for assessing chemically induced mutagenic effects in the oral cavity of transgenic Big Blue® rats. Environ Mol Mutagen 56(7):629-636; doi: 10.1002/em.21951. PMID: 25969955.

Borghoff SJ, Poet TS, Green S, Davis J, Hughes B, Mensing T, Sarang SS, Lynch AM, Hard GC. 2015. Methyl isobutyl ketone exposure-related increases in specific measures of α2u-globulin (α2u) nephropathy in male rats along with in vitro evidence of reversible protein binding. Toxicology 333(July 3):1-13; doi: 10.1016/j.tox.2015.02.003. PMID: 25797582.

Patlewicz G, Simon T, Rowlands JC, Budinsky R, Becker RA. 2015. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes. Regul Toxicol Pharmacol 71(3):463-477; doi: 10.1016/j.yrtph.2015.02.011. PMID: 25707856. (Top 10 Paper for RASS Award at SOT 2016)

Hughes BJ, LeBaron MJ, Thomas J, Kan HL, Lynch AM, Borghoff SJ, Green S, Mensing T, et al. 2015. Activation of CAR and PXR nuclear receptors in the liver of MIBK-exposed mice. Presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Proctor DM, Suh M, Campleman SL, Thompson CM. 2014. Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures. Toxicology 325(Nov):160-179; doi: 10.1016/j.tox.2014.08.009. PMID: 25174529.

Wilson VS, Keshava N, Hester S, Segal D, Chiu W, Thompson CM, Euling SY. 2013. Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment. Toxicol Appl Pharmacol 271(3):299–308; doi: 10.1016/j.taap.2011.01.017. PMID: 21295051.

Proctor DM, Suh M, Thompson CM, Harris MA. 2013. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at Society of Toxicology 52nd Annual Meeting, March 10-14, San Antonio, TX.

Thompson CM, Proctor DM, Suh M, Haws LC, Kirman CR, Harris MA. 2013. Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. Crit Rev Toxicol 43(3):244-274; doi: 10.3109/10408444.2013.768596. PMID: 23445218.

Maier A, Kohrman-Vincent M, Hertzberg R, Allen B, Haber LT, Dourson M. 2012. Critical review of dose-response options for F344 rat mammary tumors for acrylamide – Additional insights based on mode of action. Food Chem Toxicol 50(5):1763–1776; doi: 10.1016/j.fct.2012.02.002.

Proctor DM, Thompson CM, Suh M, Haws LC, Harris MA. 2012. Mode of action for intestinal carcinogenesis of ingested hexavalent chromium in mice. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

Thompson CM, Proctor DM, Suh M, Haws LC, Hebert CD, Mann JF, Shertzer HG, Hixon JG, Harris MA. 2012. Comparison of the effects of hexavalent chromium in the alimentary canal of F344 rats and B6C3F1 mice following exposure in drinking water: Implications for carcinogenic modes of action. Toxicol Sci 125(1):79-90; doi: 10.1093/toxsci/kfr280. PMID: 22011396.

Robison TW. 2011. Dealing with positive in vitro mammalian cell genotoxicity assays. Inter Drug Discovery 6(5):40-43.

Enayetallah AE, Ziemek D, Leininger MT, Randhawa R, Yang J, Manion TB, Mather DE,…, Greene N, et al. 2011. Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform. PLoS One 6(11):e27009; doi: 10.1371/journal.pone.0027009. PMID: 22073239.

Thompson CM, Proctor DM, Haws LC, Hebert CD, Grimes SD, Shertzer HG, Kopec AK, Hixon JG, Zacharewski TR, Harris MA. 2011. Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium. Toxicol Sci 123(1):58-70; doi: 10.1093/toxsci/kfr164. PMID: 21712504.

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Hinerman J, Herr A. Determining the mechanism of activation of glycoprotein VI. Poster presented to the Ohio Valley Crystallographic Symposium Meeting, Cleveland, OH, November 2011.

Proctor D, Meek B. Using mode of action data to guide quantitative cancer risk assessment: A case study of hexavalent chromium in drinking water. Presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.